BeiGene price target raised to $259 from $207 at Bernstein
Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...
Sutro Biopharma (STRO) was downgraded to a Hold Rating at JMP Securities
Sutro Biopharma (STRO – Research Report) received a Hold rating and price target from JMP Securities analyst Reni Benjamin today. The ...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles ...
Targeted Oncology11h
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.